



## Dynamic CpG methylation of the KCNQ1OT1 gene during maturation of human oocytes

R Khoureiry, S Ibala-Rhondane, L Méry, T Blachère, J-F Guérin, J Lornage and A Lefèvre

*J. Med. Genet.* 2008;45:583-588;  
doi:10.1136/jmg.2008.057943

---

Updated information and services can be found at:  
<http://jmg.bmj.com/cgi/content/full/45/9/583>

---

*These include:*

### References

This article cites 34 articles, 16 of which can be accessed free at:  
<http://jmg.bmj.com/cgi/content/full/45/9/583#BIBL>

### Rapid responses

You can respond to this article at:  
<http://jmg.bmj.com/cgi/eletter-submit/45/9/583>

### Email alerting service

Receive free email alerts when new articles cite this article - sign up in the box at the top right corner of the article

---

### Correction

A correction has been published for this article. The contents of the [correction](#) have been appended to the original article in this reprint. The correction is also available online at:  
<http://jmg.bmj.com/cgi/content/full/45/12/832-b>

---

### Notes

---

To order reprints of this article go to:  
<http://journals.bmj.com/cgi/reprintform>

To subscribe to *Journal of Medical Genetics* go to:  
<http://journals.bmj.com/subscriptions/>

# Dynamic CpG methylation of the *KCNQ1OT1* gene during maturation of human oocytes

R Khoureiry,<sup>1</sup> S Ibal-Rhomdane,<sup>1,2</sup> L Méry,<sup>1</sup> T Blachère,<sup>1</sup> J-F Guérin,<sup>1</sup> J Lornage,<sup>1</sup> A Lefèvre<sup>1</sup>

<sup>1</sup>INSERM U846, Laboratoire de Biologie de la Reproduction, Faculté de Médecine, Lyon, France; <sup>2</sup>Service de Cytogénétique et Biologie de la Reproduction, CHU Farhat Hached, Sousse, Tunisia

Correspondence to:  
Dr A Lefèvre, INSERM U846, Laboratoire de Biologie de la Reproduction, Faculté de Médecine, 8 avenue Rockefeller, 69373 Lyon cedex 8, France; [annick.lefevre@inserm.fr](mailto:annick.lefevre@inserm.fr)

RK and SI-R contributed equally to this work

Received 25 January 2008  
Revised 10 April 2008  
Accepted 21 April 2008

## ABSTRACT

**Background:** Imprinted genes, many of which are involved in development, are marked during gametogenesis to allow their parent-of-origin specific expression, and DNA methylation at CpG islands is part of this epigenetic mark. Maternal imprint is apposed on oocyte during growth and maturation. Factors interfering with normal oocyte differentiation such as gonadotrophin stimulation and in vitro maturation (IVM) may possibly alter imprint resetting.

**Methods:** We examined the methylation of the *KCNQ1OT1* differentially methylated region (KvDMR1) in human oocytes at different stages of their development: germinal vesicle (GV), metaphase I (MI) or metaphase II (MII).

**Results:** About 60% of alleles were fully methylated in GV oocytes and that full imprint is acquired in most MII oocytes. Similarly to in vivo, de novo methylation of DNA occurred in vitro during oocyte maturation. Following in vitro culture for 28 h, GV and MI oocytes are significantly more methylated when they are obtained from natural cycles than from patients undergoing gonadotrophin stimulation.

**Conclusion:** This observation suggests that hyperstimulation likely recruits young follicles that are unable to acquire imprint at KvDMR1 during the course of the maturing process.

Mammalian oocytes are arrested at prophase of the first meiotic division before induction of maturation by the preovulatory luteinising hormone surge. Oocyte maturation corresponds to the re-initiation and completion of the first meiotic division, with progression from the diplotene to the metaphase II stage. It is characterised by disappearance of the germinal vesicle (GV), chromosome condensation, spindle formation, and separation of homologous chromosomes, extrusion of the first polar body, and arrest of the meiotic process at metaphase II.

To increase the number of mature oocytes, standard in vitro fertilisation (IVF) protocols require ovarian stimulation with high dosage of gonadotrophins, with the accompanying risk of developing an ovarian hyperstimulation syndrome (OHSS). Infertile women with polycystic ovaries (PCO) or polycystic ovary syndrome (PCOS) are particularly sensitive to stimulation with exogenous gonadotrophins, and are at increased risk of developing OHSS. In vitro maturation (IVM) of immature oocytes, retrieved from unstimulated ovaries, would overcome this risk. Since reports of the first successful births,<sup>1–3</sup> more than 1000 children have been born from IVM procedures, particularly in patients with PCOS.<sup>4–5</sup> However,

after IVM, the pregnancy rates remained lower than after regular IVF.<sup>6–7</sup>

Recent reports have associated artificial reproductive techniques (ARTs) with increased incidence of imprinting disorders such as Beckwith–Wiedemann syndrome (BWS),<sup>8–11</sup> Angelman syndrome,<sup>12–13</sup> and retinoblastoma<sup>14</sup> in children conceived with the use of these procedures. Genomic imprinting is an epigenetic form of gene regulation that leads to a parent-of-origin monoallelic expression of certain genes. Their allele specific expression is mainly regulated by the differential methylation of cytosine residues, within CpG dinucleotides, at differentially methylated regions (DMR).<sup>15</sup> Imprints are erased in primordial germ cells early in fetal life, and re-established according to the sex during gametogenesis. In the mouse, de novo methylation of CpG sites in DMRs occurs during the oocyte growth phase, in a size dependent manner, and with an independent timing for each imprinted gene.<sup>16–17</sup> Therefore, the use of gonadotrophin in classical IVF procedures may cause the release of immature oocytes with incomplete or labile imprints. Similarly, the establishment of maternal imprints might be affected by in vitro maturation of oocytes since embryo culture has been demonstrated to influence the methylation status and the expression of murine *H19/Igf2*<sup>18–20</sup> and *Kcnq1ot1*,<sup>19</sup> and human oocytes matured in vitro harboured methylation at *H19* DMR1.<sup>21</sup>

*KCNQ1OT1* lies on human chromosome 11p15.5, a region organised into two domains controlled by two distinct imprinting control regions, DMR1 and KvDMR1. DMR1 is methylated on the paternal allele and regulates the expression of *H19/IGF2*. KvDMR1 is located in the promoter of the non-coding *KCNQ1OT1* gene and is maternally methylated. *KCNQ1OT1* is paternally expressed and is thought to regulate negatively the expression of several maternally expressed genes.<sup>22</sup> Loss of methylation (LOM) on the maternal allele has been observed in 40–50% of all sporadic BWS cases<sup>23–25</sup> and in the majority of BWS patients conceived through ART.<sup>10–11</sup> To evaluate the impact of either ovarian stimulation with gonadotrophin or in vitro maturation on the establishment and/or maintenance of the maternal imprint, we analysed the methylation profile of the imprinting centre KvDMR1 in human oocytes at different phases of their maturation.

## MATERIAL AND METHODS

### Source of human oocytes and embryos


The oocytes were donated for research by patients of Laboratoire de Biologie de la Reproduction at

Edouard Hériot Hospital, after they had given their consent. A total of 167 oocytes were collected from 52 patients included in an intracytoplasmic sperm injection (ICSI) protocol and undergoing standard long term stimulation with follicle stimulating hormone (FSH) and human chorionic gonadotrophin (HCG). Most of the women do not have any known infertility problems, but 11 suffered from PCO, three from dysovulation, four had endometriosis, and one autoimmune lupus. The oocytes collected for research were immature (either at germinal vesicle (GV) or at metaphase I (MI)), or at metaphase II (MII) stages. Immature oocytes were either directly saved for methylation analysis or matured in vitro during a 28 h period<sup>26</sup> before analysis. A total of 70 oocytes were collected from patients with PCO during natural cycles, following a 28 h culture in vitro. The in vitro medium was from Medicult R (Mollehaven, Jyllingy, Denmark) supplemented with FSH, HCG, and 10% serum from the patient. The oocytes were denuded of cumulus cells by repeated pipetting in a hyaluronidase solution (150 units, type VII; Sigma, La Chapelle sur Erdre, France). Zona pellucida and any remaining somatic cells attached were removed by digestion with proteinase K (9 units/ml). One to six oocytes at the same stage of maturation and from the same cycle were pooled.

#### DNA methylation analysis

The methylation profile of KvDMR1 was determined by bisulfite mutagenesis and sequencing as previously described.<sup>21</sup> We analysed a total of 22 CpG sites in a 260 bp fragment (66531–66801 bp, U90095) following nested polymerase chain reaction (PCR). To set up the bisulfite sequencing technique at the single cell level, particular care was taken in the choice of primers for nested PCR: selected external primers should typically give a good signal on agarose gel, starting with 1 ng of bisulfite treated genomic DNA, and internal primers should give a signal amplifying the first PCR product obtained with 10 pg of genomic DNA. Primers specific for bisulfite converted DNA: external forward, 5'-TGTTTTTGTAGTTTATATGG AAGGGTTAA-3'; external reverse, 5'-CTCACCCCTAAAAA CTTAAAACCTC-3'; internal forward, 5'-GTTAGGGAAGTT TTAGGGTGTGAAT-3'; internal reverse, 5'-AAACATACC AAACCACCCACCTAACAAA-3'.

**Figure 1** (A) Map of the 11p15 imprinted region comprising KvDMR1. The enlargement below the map shows the position of the differentially methylated CpGs analysed as well as Paul and Tail sites. Base numbering is according to GenBank accession number U90095. (B) Bisulfite sequencing analysis of KvDMR1 in lymphocytes, cumulus cells and spermatozoa. Each line represents a single allele. A black square indicates a methylated CpG, an open square denotes an unmethylated CpG.



The PCR products were cloned into pGEM-T (Promega) and sequenced. Four to six clones were sequenced for each product. Because of the limiting starting material and the destruction of the DNA that is inherent to bisulfite treatment, identical sequences from separated PCRs are certain to represent distinct chromosomes, but identical sequences from one product are counted only once, as previously discussed<sup>27</sup> The frequency of the two methylation states found in different oocyte populations were analysed using distribution free tests.<sup>28</sup>

Approximately 100 ng of the same PCR product used for cloning and sequencing was digested with Tail (ACGT/) and Paul (G/CGCGC).


## RESULTS

### Analysis of the methylation status of KvDMR1 in oocytes from stimulated cycles

To determine whether the maternal methylation profile of imprinted genes was established in fully grown GV oocytes and whether the 28 h culture period necessary to mature GV oocytes in vitro could influence the establishment/maintenance of the imprint, we examined the methylation pattern of the KvDMR1 region in oocytes at GV, MI or MII stages, retrieved from stimulated cycles. A total of 167 oocytes from 52 stimulated cycles were included in this study. Eleven patients had PCO, three suffered from dysovulation, two from endometriosis, one had an autoimmune lupus, and the other 33 exhibited normal fertility parameters. Forty oocytes at the GV stage from 12 patients (mean (SD) age 31.36 (1.36) years), 27 oocytes at the MI stage from 12 patients (30.25 (1.38) years), and 19 oocytes at the MII stage from three patients (31.11 (1.66) years) were collected for analysis immediately after retrieval. The methylation status of a 22 CpG site segment within KvDMR1 (fig 1A) was determined using bisulfite sequencing analysis adapted to the single cell level. KvDMR1 is unmethylated in spermatozoa, as expected, and both methylated and unmethylated alleles were equally obtained from either lymphocytes or cumulus cells (fig 1B), which exclude any bias in the PCR amplification between methylated and unmethylated strands. Optimisation of the bisulfite sequencing protocol at the few-cell level allow us to analyse oocytes (1–3 oocytes per PCR amplification cycle) from each

**Figure 2** Methylation status of KvDMR1 in oocytes from stimulated cycles.

Bisulfite sequencing analysis was performed on oocytes at different stages of their development—germinal vesicle (GV), metaphase I (MI) or metaphase II (MII): (A) directly following collection (0 h) or (B) following in vitro culture for 28 h. The number of independent experiments (n =) and the total number of oocytes analysed are indicated for each stage. Each row of squares represents a single allele. A black square indicates a methylated CpG, an open square denotes an unmethylated CpG. The numbers on the right correspond to the polymerase chain reaction (PCR) products shown below each diagram, uncut (a) or following digestion with Tail (b) or Paul (c). Dynamics of methylation change during oocyte maturation is summarised in the diagrams below the figure. In panel B, encircled alleles are from patients with polycystic ovaries; they correspond to four independent PCRs performed on 15 oocytes' DNA for GV and three independent PCRs performed on eight oocytes' DNA for MI. For each sample, the methylation data were analysed by computing the percentage of methylated CpGs out of the total number of CpGs analysed and subjected to statistical analysis using distribution free tests.<sup>28</sup>



patient individually. The efficiency of PCR amplification was 63.8% (99 positive PCR amplifications/155). Fully grown GV oocytes (120–150  $\mu$ m in humans) exhibited heterogeneous methylated profiles, with 62.5% of the alleles being methylated, corresponding to 60.4% of the total CpG sites analysed (319/528) (fig 2A). The percentage of methylated alleles in MI oocytes was more elevated than in GV oocytes (66.6%/62.5%, corresponding to 308 methylated CpG sites/462 analysed CpGs;  $p < 0.01$ ) (table 1). In contrast, most alleles were methylated in MII oocytes (89.5%, corresponding to 364 methylated CpG sites/418 analysed CpGs), although two alleles from two different patients remained hypomethylated at this last stage of oocyte differentiation before fertilisation. Therefore, de novo methylation of KvDMR1 occurred with meiosis II progression.

To evaluate the effect of in vitro culture on the ontogeny of the methylation at KvDMR1, GV oocytes retrieved from

patients treated with gonadotrophins for ICSI were cultured in an in vitro maturing medium for 28 h.<sup>26</sup> At the end of the culture period, the oocytes either stayed at the GV stage of their first meiotic division (37 oocytes from 10 patients, four of which had PCO; 32.38 (0.87) years) or remained arrested at the MI stage (20 oocytes from eight patients, three of which had PCO; 28.75 (1.29) years) or undergo their second meiotic division up to the normal block before fertilisation at MII (24 oocytes from 12 patients, 32.08 (1.23) years). Following this 28 h culture period, arrested GV or MI oocytes exhibited a heterogeneous methylated profile similar to oocytes at the same stage which were not subjected to in vitro culture (61.2%/62.5% methylated alleles, corresponding to 408 methylated CpG sites/682 analysed CpGs compared to 319/528,  $p > 0.05$  for GV and 65.2%/66.6% methylated alleles, corresponding to 327 methylated CpG sites/506 analysed CpGs compared to 308/462,  $p > 0.05$  for MI

oocytes) (fig 2B) (table 1). De novo methylation of KvDMR1 also occurred in MII oocytes matured in vitro, but the methylation level was lower in this case (78.3%/89.5% methylated alleles, corresponding to 380 methylated CpG sites/506 analysed CpGs compared to 364/418;  $p < 0.01$ ). It is of note that the methylation level of GV and MI oocytes from stimulated PCO patients (encircled alleles in fig 2B) matched that of the total population of in vitro cultured GV and MI oocytes from stimulated cycles (62.5%/61.2% methylated alleles, corresponding to 107 methylated CpG sites/176 analysed CpGs compared with 408/682 for GV  $p \geq 0.9$  and 63.6%/65.2% methylated alleles, corresponding to 157 methylated CpG sites/242 analysed CpGs compared with 327/506 for MI,  $p \geq 0.9$ ).

Because the bisulfite treatment was done on a limited number of copies, restriction analysis with enzymes that cleave only the methylated template was performed to verify that the sequencing results reflect the overall methylation profile of KvDMR1 in the oocytes analysed. Digestion with *Paul* (G/CGCGC) and *TaiI* (ACGT/) were carried out on every PCR product before cloning. As can be seen in the examples shown under the methylation profiles for each group of oocytes (fig 2), if the sequencing shows only unmethylated profiles, the PCR product was not cut by both enzymes and appears on agarose gel as a band of 291 bp; methylated templates gave fully digested bands, *Paul* generates two fragments of 195 and 95 bp, *TaiI* generates two fragments of 161 and 129 bp; and digestion of heterogenous methylated templates revealed a mixture of uncut and cut products. With the reservation that this gives information on four CpG sites only, the results of restriction enzyme analysis are analogous to those obtained from sequencing, excluding any bias during cloning.

#### Analysis of the methylation status of KvDMR1 in oocytes from unstimulated cycles

To determine the possible interference of gonadotrophin treatments with the ontogeny of methylation at KvDMR1, we examined the methylation pattern of 70 oocytes that were retrieved from 16 natural cycles in women with PCOs and underwent in vitro maturation. MII oocytes were not available for analysis because they were subjected to sperm injection in the course of the parental project of the couple. Oocytes remaining arrested at GV (36 oocytes from nine patients, 29.5 (0.85) years) or MI stages (34 oocytes from eight patients, 30.5 (0.97) years) were de facto excluded from the parental project and were included in the study. Following a 28 h culture period, the percentage of methylated alleles was significantly increased in MI oocytes compared to GV oocytes (70.3%/67.8%, corresponding to 413 methylated CpG sites/594 analysed CpGs compared to 414/616;  $p < 0.01$ ) and KvDMR1 was significantly more methylated in GV oocytes retrieved from natural cycles than in GV oocytes from stimulated patients

(67.8%/61.2% methylated alleles, corresponding to 414 methylated CpG sites/616 analysed CpGs compared to 408/682;  $p < 0.001$ ) (fig 3) (table 1). This is also true when only GV from PCOs stimulated patients are considered (67.8%/62.5% methylated alleles, corresponding to 107 methylated CpG sites/176 analysed CpGs compared to 414/616;  $p < 0.01$ ) (fig 2B and fig 3). Likewise, KvDMR1 is more methylated in MI oocytes from natural cycles than from stimulated cycles in both the general population (70.3%/65.2% methylated alleles, corresponding to 413 methylated CpG sites/594 analysed CpGs compared to 327/506;  $p < 0.01$ ) and the PCO population (70.3%/63.6% methylated alleles, corresponding to 413 methylated CpG sites/594 analysed CpGs compared to 157/242;  $p < 0.01$ ).

As previously explained, digestions with *Paul* and *TaiI* were carried out on each PCR product to be cloned and sequenced, and results of restriction enzyme analysis are comparable to those obtained from sequencing (examples are given under the methylation profiles of each group of oocytes in fig 3).

#### DISCUSSION

A series of recent observations has indicated an increased risk of conceiving a child with an imprinting defect leading to several diseases and syndromes in couples who procreated using ART. In particular, the risk of BWS was up to nine times greater in the ART population than in the general population.<sup>29</sup> BWS is characterised by pre- and/or postnatal overgrowth, a series of abnormalities, and a predisposition to embryonal tumours (MIM 130650). ART related BWS is specifically associated with loss of maternal methylation at the KvDMR1 imprinting control region. In all the published cases of ART related BWS, no common factor could be identified—the causes of infertility, the stimulatory protocol, the culture media used, the biological technique, as well as the timing of embryo transfer varied.<sup>10 11 29</sup> The only general feature is the use of ovarian stimulation protocol and, in most of the cases, of in vitro culture. IVM of immature oocytes retrieved from unstimulated ovaries may overcome a possible disturbing effect of hormonal stimulation on methylation of the maternal genome, but will not eliminate the potential risk associated with the in vitro culture of the oocytes. The availability of immature oocytes at the GV or MI stages from stimulated and unstimulated cycles gave us an opportunity to appreciate the impact of each factor on the methylation status of KvDMR1.

We first show that the hypermethylated pattern characteristic of the maternal allele of KvDMR1 in somatic cells is only established in two thirds of total alleles analysed in fully grown GV oocytes from stimulated cycles. These results are apparently divergent from those of Geuns *et al*<sup>30</sup> who showed a fully methylated pattern in GV oocytes. The discrepancy between both studies could be due to the small number of independent alleles randomly sequenced in Geuns *et al*<sup>30</sup> (seven for GV and seven for MI in Geuns *et al*<sup>30</sup> compared to 55 and 44, respectively, in this study). More likely, since the region analysed by this group is situated 1239 bp downstream from the region in the present study, it may reflect a dichotomy between two regions within the DMR whose imprinting schedule would be dissociated. The fact that methylation would not occur by linear spreading along the chromosome has been previously documented for the H19-Igf2 locus: a hierarchy in the methylation process has been observed during early post-implantation development, the methylation of DMR1 preceding that of DMR2 in the kidney.<sup>31</sup>


In mice, KvDMR1 is entirely methylated in early antral follicles, before meiosis resumption.<sup>17</sup> This contrast between

**Table 1** Percentage of methylated alleles in germinal vesicle (GV), metaphase I (MI) and metaphase II (MII) oocytes in the different experimental situations

	Stimulated cycles			Unstimulated cycles PCO/matured in vitro
	Matured in vivo	Matured in vitro	PCO/matured in vitro	
GV	62.5	61.2	62.5	67.8
MI	66.6	65.2	63.6	70.3
MI	89.5	78.3	–	–

PCO, polycystic ovaries.

**Figure 3** Methylation status of KvDMR1 in oocytes obtained from natural cycles in patients with polycystic ovaries (PCO). Only germinal vesicle (GV) and metaphase I (MI) oocytes could be analysed. Details are described in fig 2. Comparisons with results obtained from stimulated cycles in all patients or in PCO patients only are summarised in the diagram. For each sample, the methylation data were analysed by computing the percentage of methylated CpGs out of the total number of CpGs analysed and subjected to statistical analysis using distribution free tests.<sup>28</sup>



mice and humans emphasises the need for studies on humans. De novo methylation progresses through meiosis I and II, and almost all matured MII oocytes were fully methylated at KvDMR1. As a few DNA copies remained unmethylated at the MII stage, we cannot exclude the possibility that maternal methylation of KvDMR1 could occur at later stages. Some of the oocytes that were immature at the time of collection succeeded in completing maturation in vitro within 28 h. Since the imprint was not thoroughly established in fully grown GV oocytes, we wondered whether the culture media could influence the de novo methylation of KvDMR1. Following in vitro culture, immature oocytes from stimulated cycles that remained at the GV stage or progressed to MI exhibited the same degree of methylation than oocytes matured in vivo, but MII oocytes showed a significant deficit in methylation. Several hypotheses may account for this observation. It could be attributed to the shorter time given to GV oocytes to mature in vitro compared to the in vivo maturing period (28 h/36–40 h), which does not allow the methylation process to go to completion. On the other hand, prolonged culture of MII oocytes has been shown to induce demethylation of Peg1/Mest DMR in the mouse.<sup>32</sup>

In the natural human menstrual cycle about 15 follicles are recruited for growth. After some 14 days, only one or two of these follicles reach maturation and are ovulated. In standard ART, the large dose of gonadotrophins used to rescue the growth of small follicles could cause the premature release of oocytes that are at an earlier developmental stage. These oocytes have escaped selection and may not be able to overtake their delay in acquisition of the imprint and therefore exhibit a hypomethylated pattern at MII. The hypothesis that gametic imprints are sensitive to in vitro conditions is supported by previous work: a gain of methylation has been described at H19/Igf2 DMR following in vitro culture of preimplantation embryos, couple with altered development,<sup>19, 33</sup> and a loss of methylation at the Igf2R and Peg1/Mest loci in fully grown GV oocytes produced by in vitro development of preantral follicles.<sup>34</sup> Thus, we cannot exclude the possibility that the impaired de novo methylation of KvDMR1 observed in stimulated oocytes matured in vitro may be due in part to the composition of the culture media that does not exactly match the in vivo environment.

Oocytes obtained from unstimulated cycles have been subjected in vivo to a surge of circulating FSH that stimulates follicular recruitment, but they are collected before dominance and atresia of the subordinate follicles. They represent a valuable control to evaluate a potentially negative impact of superovulatory gonadotrophin treatments on imprint establishment. At the end of the in vitro maturing process, MII oocytes were never available because they were selected for the ICSI procedure. We observed in both GV and MI oocytes from natural cycles a significant increase in methylation as compared to oocytes at the same stage of maturation retrieved from stimulated cycles. This is particularly true when oocytes in both cycles were exclusively from POC patients; this means that the higher methylated state observed in natural cycles is not related to the aetiology of infertility—that is, PCOs in this case. One may fear that in PCO patients the oocytes recovered from natural cycles might include degenerating and atretic follicles which we did not observe. The high methylated state observed in GV and MI oocytes, and the increase of de novo methylation observed between both stages, are in favour of full imprint establishment by MII stage, though MII in vitro matured oocytes from natural cycles are not available, so it cannot be verified. The deficit of methylation in oocytes from stimulated cycles is likely to reflect the recruitment of small follicles that are at an earlier stage of development. Those oocytes may not be able to acquire full imprint by MII, even though they appeared mature in other respects and could be fertilised.

Our study on a large cohort of human oocytes demonstrated that imprint establishment proceeds during in vitro maturation, which is of particular importance for the thousands of children born from IVF oocytes. We also showed that the high concentration of gonadotrophins provided to antral follicles before recruitment to terminal growth led to the selection of some oocytes that failed to acquire full imprint at KvDMR1, particularly when they were matured in vitro, very likely because they were at an earlier stage of development. Our results are in agreement with other studies on epigenetic disorders in children born from ART that could not establish a correlation between a particular technique and the imprinting defect observed, with the exception of the hormonal treatment.

**Acknowledgements:** We thank Robert Dante and Luisa Dandolo for critical reading of the manuscript.

**Funding:** RK was a recipient of Organon and Lebanon CNRS fellowships. This work was supported by a grant from Agence de la Biomédecine "R06106CC".

**Competing interests:** None declared.

## REFERENCES

1. **Cha KY**, Koo JJ, Ko JJ, Choi DH, Han SY, Yoon TK. Pregnancy after in vitro fertilization of human follicular oocytes collected from nonstimulated cycles, their culture in vitro and their transfer in a donor oocyte program. *Fertil Steril* 1991;**55**:109–13.
2. **Trounson A**, Wood C, Kausche A. In vitro maturation and the fertilization and developmental competence of oocytes recovered from untreated polycystic ovarian patients. *Fertil Steril* 1994;**62**:353–62.
3. **Barnes FL**, Kausche A, Tiglias J, Wood C, Wilton L, Trounson A. Production of embryos from in vitro-matured primary human oocytes. *Fertil Steril* 1996;**65**:1151–6.
4. **Chian RC**. In-vitro maturation of immature oocytes for infertile women with PCOS. *Reprod Biomed Online* 2004;**8**:547–52.
5. **Le Du A**, Kadoch IJ, Bourcigaux N, Doumerc S, Bourrier MC, Chevalier N, Fanchin R, Chian RC, Tachdjian G, Frydman R, Frydman N. In vitro oocyte maturation for the treatment of infertility associated with polycystic ovarian syndrome: the French experience. *Hum Reprod* 2005;**20**:420–4.
6. **Soderstrom-Anttila V**, Makinen S, Tuuri T, Suikari AM. Favourable pregnancy results with insemination of in vitro matured oocytes from unstimulated patients. *Hum Reprod* 2005;**20**:1534–40.
7. **Cha KY**, Chung HM, Lee DR, Kwon H, Chung MK, Park LS, Choi DH, Yoon TK. Obstetric outcome of patients with polycystic ovary syndrome treated by in vitro maturation and in vitro fertilization-embryo transfer. *Fertil Steril* 2005;**83**:1461–5.
8. **Maher ER**, Brueton LA, Bowdin SC, Luharia A, Cooper W, Cole TR, Macdonald F, Sampson JR, Barratt CL, Reik W, Hawkins MM. Beckwith-Wiedemann syndrome and assisted reproduction technology (ART). *J Med Genet* 2003;**40**:62–4.
9. **Sutcliffe AG**, Peters CJ, Bowdin S, Temple K, Reardon W, Wilson L, Clayton-Smith J, Brueton LA, Bannister W, Maher ER. Assisted reproductive therapies and imprinting disorders – a preliminary British survey. *Hum Reprod* 2006;**21**:1009–11.
10. **DeBaun MR**, Niemitz EL, Feinberg AP. Association of in vitro fertilization with Beckwith-Wiedemann syndrome and epigenetic alterations of LIT1 and H19. *Am J Hum Genet* 2003;**72**:156–60.
11. **Gicquel C**, Gaston V, Mandelbaum J, Siffroi JP, Flahault A, Le Bouc Y. In vitro fertilization may increase the risk of Beckwith-Wiedemann syndrome related to the abnormal imprinting of the KCN10T gene. *Am J Hum Genet* 2003;**72**:1338–41.
12. **Cox GF**, Burger J, Lip V, Mau UA, Sperling K, Wu BL, Horsthemke B. Intracytoplasmic sperm injection may increase the risk of imprinting defects. *Am J Hum Genet* 2002;**71**:162–4.
13. **Orstavik KH**, Eiklid K, van der Hagen CB, Spetalen S, Kierulf K, Skjeldal O, Buiting K. Another case of imprinting defect in a girl with Angelman syndrome who was conceived by intracytoplasmic semen injection. *Am J Hum Genet* 2003;**72**:218–9.
14. **Moll AC**, Imhof SM, Cruysberg JR, Cruysberg JR, Schouten-van Meeteren AY, Boers M, van Leeuwen FE. Incidence of retinoblastoma in children born after in-vitro fertilisation. *Lancet* 2003;**361**:309–10.
15. **Reik W**, Walter J. Genomic imprinting: parental influence on the genome. *Nat Rev Genet* 2001;**2**:21–32.
16. **Lucifero D**, Mann MR, Bartolomei MS, Trasler JM. Gene-specific timing and epigenetic memory in oocyte imprinting. *Hum Mol Genet* 2004;**13**:839–49.
17. **Hiura H**, Obata Y, Komiyama J, Shirai M, Kono T. Oocyte growth-dependent progression of maternal imprinting in mice. *Genes Cells* 2006;**11**:353–61.
18. **Khosla S**, Dean W, Brown D, Reik W, Feil R. Culture of preimplantation mouse embryos affects fetal development and the expression of imprinted genes. *Biol Reprod* 2001;**64**:918–26.
19. **Rivera RM**, Stein P, Weaver JR, Mager J, Schultz RM, Bartolomei MS. Manipulation of mouse embryos prior to implantation result in aberrant expression of imprinted genes on day 9.5 of development. *Hum Mol Genet* 2008;**17**:1–14.
20. **Fauque P**, Jouannet P, Lesaffre C, Ripoche MA, Dandolo L, Vaiman D, Jammes H. Assisted reproductive technology affects developmental kinetics, H19 imprinting control region methylation and H19 gene expression in individual mouse embryos. *BMC Dev Biol* 2007;**7**:116.
21. **Borghol N**, Lornage J, Blachere T, Sophie Garret A, Lefèvre A. Epigenetic status of the H19 locus in human oocytes following in vitro maturation. *Genomics* 2006;**87**:417–26.
22. **Horike S**, Mitsuya K, Meguro M, Kotobuki N, Kashiwagi A, Notsu T, Schulz TC, Shirayoshi Y, Oshimura M. Targeted disruption of the human LIT1 locus defines a putative imprinting control element playing an essential role in Beckwith-Wiedemann syndrome. *Hum Mol Genet* 2000;**9**:2075–83.
23. **Smilnich NJ**, Day CD, Fitzpatrick GV, Caldwell GM, Lossie AC, Cooper PR, Smallwood AC, Joyce JA, Schofield PN, Reik W, Nicholls RD, Weksberg R, Driscoll DJ, Maher ER, Shows TB, Higgins MJ. A maternally methylated CpG island in KvLQT1 is associated with an antisense paternal transcript and loss of imprinting in Beckwith-Wiedemann syndrome. *Proc Natl Acad Sci USA* 1999;**96**:8064–9.
24. **Engel JR**, Smallwood A, Harper A, Higgins MJ, Oshimura M, Reik W, Schofield PN, Maher ER. Epigenotype-phenotype correlations in Beckwith-Wiedemann syndrome. *J Med Genet* 2000;**37**:921–6.
25. **Gaston V**, Le Bouc Y, Soupre V, Burglen L, Donadieu J, Oro H, Audry G, Vazquez MP, Gicquel C. Analysis of the methylation status of the KCN10T and H19 genes in leukocyte DNA for the diagnosis and prognosis of Beckwith-Wiedemann syndrome. *Eur J Hum Genet* 2001;**9**:409–18.
26. **Mikkelsen AL**, Smith S, Lindenberg S. Possible factors affecting the development of oocytes in in-vitro maturation. *Hum Reprod* 2000;**15**(Suppl 5):11–17.
27. **Borghol N**, Blachère T, and Lefèvre A. Transcriptional and epigenetic status of protamine 1 and 2 genes following round spermatids injection into mouse oocytes. *Genomics* 2008;**91**:415–22.
28. **Kozioł JA**, Maxwell DA, Fukushima M, Colmerauer ME, Pilch YH. A distribution-free test for tumor-growth curve analyses with application to an animal tumor immunotherapy experiment. *Biometrics* 1981;**37**:383–90.
29. **Halliday J**, Oke K, Breheny S, Algar E, J Amor D. Beckwith-Wiedemann syndrome and IVF: a case-control study. *Am J Hum Genet* 2004;**75**:526–8.
30. **Geuns E**, Hilven P, Van Steirteghem A, Liebaers I, De Rycke M. Methylation analysis of KvDMR1 in human oocytes. *J Med Genet* 2007;**44**:144–7.
31. **Lopes S**, Lewis A, Hajkova P, Dean W, Oswald J, Forné T, Murrell A, Constancia M, Bartolomei M, Walter J, Reik W. Epigenetic modifications in an imprinting cluster are controlled by a hierarchy of DMRs suggesting long-range chromatin interactions. *Hum Mol Genet* 2003;**12**:295–305.
32. **Imamura T**, Kerjean A, Heams T, Kupiec JJ, Thenevin C, Paldi A. Dynamic CpG and non-CpG methylation of the Peg1/Mest gene in the mouse oocyte and preimplantation embryo. *J Biol Chem* 2005;**280**:20171–5.
33. **Doherty AS**, Mann MR, Tremblay KD, Bartolomei MS, Schultz RM. Differential effects of culture on imprinted H19 expression in the preimplantation mouse embryo. *Biol Reprod* 2000;**62**:1526–35.
34. **Kerjean A**, Couvert P, Heams T, Chalas C, Poirier K, Chelly J, Jouannet P, Paldi A, Poirrot C. In vitro follicular growth affects oocyte imprinting establishment in mice. *Eur J Hum Genet* 2003;**11**:493–6.

Access all our original articles online even before they appear in a print issue!

Online First is an exciting innovation that allows the latest clinical research papers to go from acceptance to your browser within days, keeping you at the cutting edge of medicine.

Simply follow the Online First link on the homepage and read the latest Online First articles that are available as unedited manuscripts in downloadable PDF form. The articles are peer reviewed, accepted for publication and indexed by PubMed but not yet included in a journal issue, so you'll be among the first to read them!

## CORRESPONDENCE

## No reason yet to change diagnostic criteria for Noonan, Costello and cardio-facio-cutaneous syndromes

The clinicogenetic relationship between Noonan syndrome (NS) and Noonan-like syndromes (Costello syndrome (CS), cardio-facio-cutaneous (CFC syndrome) and the disruption of the RAS-ERK pathway makes for a fascinating story that has developed over the past decade, and is still developing. The discovery that the genes causing these syndromes encode proteins that converge on the same metabolic pathway facilitated understanding of the similarities that group these conditions within one family of syndromes.<sup>1</sup> Nevertheless, their nosological classification continues to be a challenge. There is general agreement that NS is caused by mutations of *PTPN11* (most cases), *SOS1* or *RAF1*, that CFC syndrome is caused by mutations of *BRAF* (most cases), *MEK1* or *MEK2*, and that CS is caused by mutations of *HRAS*. Cases due to *KRAS* mutations are of uncertain nosological classification, and there are some borderline cases for which the clinical diagnosis will be uncertain even for the best experts in the field.

The recent article by Nyström *et al*<sup>2</sup> represents another attempt at bringing some order within this complex matter. However, we think that some of the conclusions drawn by the authors are unwarranted. The main focus of this letter is on patients 3 and 8 of that study, who are unusual because, according to the authors, the former has CFC syndrome caused by a mutation in *SOS1*, and the latter has NS, caused by a mutation in *BRAF*.<sup>2</sup> The inescapable conclusion is a further expansion of the genetic heterogeneity of both syndromes. However, it is an arguable conclusion. Although we can judge only on the basis of a very sparse clinical description in the table and small photographs in the first figure, our impression is that patient 3 is a typical case of *SOS1* NS (no mental delay, no curly hair, dry skin, missing eyebrows), and patient 8 is an ordinary case of CFC syndrome due to *BRAF* mutation (mental delay, curly hair, other typical features). Nyström *et al*<sup>2</sup> state that their clinical diagnoses were based on criteria established by Roberts *et al*,<sup>3</sup> but they had to make exceptions (arbitrarily) on at least

two criteria: mental delay and curly hair. Moreover, they did not consider that Roberts *et al*<sup>3</sup> published their criteria before the discovery of *SOS1*,<sup>4</sup> which established the association between NS and pronounced skin involvement. Moreover, it should be pointed out that Nyström *et al*<sup>2</sup> based their diagnoses of CFC or NS solely on presence or absence of ectodermal signs that by themselves do not capture the complexity of these phenotypes, resulting occasionally in misdiagnosis.

Based on these considerations, we see no reason, at the moment, to change the generally held view that NS can be caused by mutations in three different genes (*PTPN11*, *SOS1*, *RAF1*), CFC syndrome by mutations in another three genes (*BRAF*, *MEK1*, *MEK2*), and CS by *HRAS* mutations, with *KRAS* mutations causing rather atypical cases that are difficult to classify. As Nyström *et al*<sup>2</sup> did not discuss CS in their report, it is surprising and difficult to understand why they indicate that this condition can be caused not only by *HRAS* mutations, but also by mutations in *KRAS*, *BRAF* and *MEK1* (their third figure). There is general agreement that the diagnosis of CS should be restricted to those cases that carry a *HRAS* mutation,<sup>5</sup> which implies increased risk for cancer and consequent application of a strict surveillance protocol. Again, there is no reason, at the moment, to change this stance.

G Neri,<sup>1</sup> J Allanson,<sup>2</sup> M I Kavamura<sup>3</sup>

<sup>1</sup>Istituto di Genetica Medica, Università Cattolica del S. Cuore, Roma, Italy; <sup>2</sup>Department of Genetics, Children's Hospital of Eastern Ontario, Ottawa, ON, Canada; <sup>3</sup>Mercidical Genetics Center, Federal University of Sao Paulo, Sao Paulo, Brazil

**Correspondence to:** Dr G Neri, Istituto di Genetica Medica, Università Cattolica, Largo F. Vito, 1 00168 Roma, Italy; [gneri@rm.unicatt.it](mailto:gneri@rm.unicatt.it)

Received 12 September 2008

Accepted 19 September 2008

*J Med Genet* 2008;**45**:832. doi:10.1136/jmg.2008.063263

## REFERENCES

1. Gelb BD, Tartaglia M. Noonan syndrome and related disorders: dysregulated RAS-mitogen activated protein kinase signal transduction. *Hum Mol Genet* 2006;**15**:R220–6.
2. Nyström A-M, Ekvall S, Berglund E, Björkvist M, Braathen G, Duchon K, Enell H, Holmberg E, Holmlund U, Olsson-Engman M, Annerén G, Bondeson M-L. Noonan and cardio-facio-cutaneous syndromes: two clinically and genetically overlapping disorders. *J Med Genet* 2008;**45**:500–6.

3. Roberts A, Allanson J, Jadico SK, Kavamura MI, Noonan J, Opitz JM, Young T, Neri G. The cardio-facio-cutaneous syndrome (CFC): a review. *J Med Genet* 2006;**43**:833–42.
4. Tartaglia M, Pennacchio LA, Zhao C, Yadav KK, Fodale V, Sarkozy A, Pandit B, Oishi K, Martinelli S, Schackwitz W, Ustaszewska A, Martin J, Bristol J, Carta C, Lepri F, Neri C, Vasta I, Gibson K, Curry CJ, Siguero JP, Digilio MC, Zampino G, Dallapiccola B, Barsagi D, Gelb BD. Gain-of-function *SOS1* mutations cause a distinctive form of Noonan syndrome. *Nat Genet* 2007;**39**:75–9.
5. Kerr B, Allanson J, Delrue MA, Gripp KW, Lacombe D, Lin AE, Rauhen KA. The diagnosis of Costello syndrome: nomenclature in Ras/MAPK pathway disorders. *Am J Med Genet* 2008;**146A**:1218–20.

## CORRECTIONS

doi:10.1136/jmg.2005.036178corr1

Lugtenberg D, de Brouwer APM, Kleefstra T, Oudakker AR, Frints SGM, Schrandt-Stumpel CTRM, Fryns JP, Jensen LR, Chelly J, Moraine C, Turner G, Veltman JA, Hamel BCJ, de Vries BBA, van Bokhoven H, Yntema HG. Chromosomal copy number changes in patients with non-syndromic X linked mental retardation detected by array CGH. *J Med Genet* 2006;**43**:362–70.

There was an error in an article published in the April 2006 issue of the journal. The authors reported possible duplication of copy number polymorphisms flanking the *MECP2* region. These duplications were observed by multiplex ligation-dependent probe amplification (MLPA) in one patient and two controls (figure 2). Recent further investigations of these regions have shown that these duplications were false observations. Newly synthesised MLPA probes and better quality DNA samples showed no extra DNA copies in the region. From reanalysis of the previously obtained MLPA data, the authors conclude that the fluorescence intensity signals were outside the normal range in which the data can be correctly interpreted (100–1000) for current quality-control thresholds (>10000). The authors regret this incorrect interpretation of the data.

doi:10.1136/jmg.2008.057943corr1

There was an error in an author's name in an article published in the September issue of the journal (Khoueir R, Ibala-Rhondane A, Méry L, Blachère T, Guérin J-F, Lornage J, Lefèvre A. Dynamic CpG methylation of the *KCNQ10T1* gene during maturation of human oocytes. *J Med Genet* 2008; **45**:583–8). The name of the first author is R Khoueir.